Movement Alert｜BioNTech SE Overnight Rise 5.5%, Breast Cancer Combination Trial Collaboration Draws Attention

Market Focus10-26 08:17

On October 26, BioNTech SE recorded an Overnight rise of 5.5%, trading at $92.96/share, with turnover of $541.0.

The move followed recent disclosure that BioNTech SE partnered with Gilead Sciences to evaluate its experimental drug pumitamig in combination with Trodelvy as a first-line treatment for advanced triple-negative breast cancer.

Under the plan announced on October 22, BioNTech SE intends to amend the Phase 3 ROSETTA Breast-01 trial by replacing chemotherapy with Trodelvy, subject to regulatory approval. BioNTech SE will continue to sponsor and lead the study, while Gilead will supply Trodelvy. The company said this would be the first global Phase 3 trial testing pumitamig with an antibody-drug conjugate. The combination remains investigational, and safety and efficacy have not been established.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment